Sunday, October 4, 2009

Combination of Depagliflozin & Metaformin for type 2 diabatic ?

We knew that these two Depagliflozin (left) & Metaformin (right) compounds were being studied independently for type 2 diabetic condition. Dapagliflozin, an investigational compound, is a potential first-in-class SGLT2 inhibitor currently in Phase 3 trials under joint development as a once-daily oral therapy for the treatment of type 2 diabetes. SGLT2 inhibitors facilitate the elimination of glucose by the kidney, thereby returning serum glucose levels towards normal.

A recent study (24-week phase 3 clinical study by Bristol-Myers Squibb Company and AstraZeneca) demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin. Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor.

The study also showed that individuals receiving dapagliflozin had statistically greater mean reductions in body weight compared to individuals taking placebo. Results from the 24-week study were presented at the 45th European Association for the Study of Diabetes Annual Meeting. This is the first public presentation of dapagliflozin Phase 3 data.

More interestingly, data on weight loss and blood pressure may be important adjuvants to glycemic control and is of great importance and hope in the days to come the SGLT2 inhibitors ( improved glycemic control) will play an important role in the type 2 diabetes. Given the continued rising prevalence of type 2 diabetes, there is an urgent need to have drugs of this kind..

Ref : http://www.astrazeneca.com/media/latest-press-releases/Dapagliflozen_Study014_EASD?itemId=7108139

No comments:

Post a Comment